Zongertinib, a HER2 TKI, demonstrated clinically meaningful activity and tolerability in patients with NSCLC with and without brain metastases harboring a HER2 mutation.
Beth Sandy, MSN, CRNP, FAPO Thoracic Oncology Nurse Practitioner Abramson Cancer Center, University of Pennsylvania Philadelphia, PA
Sponsored by
To sign up for our newsletter or print publications, please enter your contact information below.
